Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Burris

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Investigational New Drugs|September 18, 1998
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumorsN W Peacock, H A Burris, V Dieras, et al.
Cancer|October 12, 2001
Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research NetworkF A Greco, H A Burris, J R Gray, et al.
Cancer|April 3, 1999
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinomaJ D Hainsworth, H A Burris, J B Erland, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2011
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumorsJ R Infante, R Kurzrock, J Spratlin, et al.
Cancer Research|December 15, 1993
A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignanciesD W Shaffer, L S Smith, H A Burris, et al.
Journal of the National Cancer Institute|October 5, 1994
Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming unitsP W Cobb, D R Degen, G M Clark, et al.
British Journal of Cancer|November 18, 2010
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaA Younes, J M Vose, A D Zelenetz, et al.
The Cancer Journal From Scientific American|August 10, 1999
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trialP J Hesketh, J J Crowley, H A Burris, et al.
Anti-Cancer Drugs|July 1, 1997
Phase I study with the DNA sequence-specific agent adozelesinH A Burris, V C Dieras, M Tunca, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationD A Rinaldi, J G Kuhn, H A Burris, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Investigational New Drugs|September 18, 1998
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumorsN W Peacock, H A Burris, V Dieras, et al.
Cancer|October 12, 2001
Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research NetworkF A Greco, H A Burris, J R Gray, et al.
Cancer|April 3, 1999
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinomaJ D Hainsworth, H A Burris, J B Erland, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2011
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumorsJ R Infante, R Kurzrock, J Spratlin, et al.
Cancer Research|December 15, 1993
A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignanciesD W Shaffer, L S Smith, H A Burris, et al.
Journal of the National Cancer Institute|October 5, 1994
Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming unitsP W Cobb, D R Degen, G M Clark, et al.
British Journal of Cancer|November 18, 2010
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaA Younes, J M Vose, A D Zelenetz, et al.
The Cancer Journal From Scientific American|August 10, 1999
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trialP J Hesketh, J J Crowley, H A Burris, et al.
Anti-Cancer Drugs|July 1, 1997
Phase I study with the DNA sequence-specific agent adozelesinH A Burris, V C Dieras, M Tunca, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationD A Rinaldi, J G Kuhn, H A Burris, et al.
Pageof 12